12:00 AM
 | 
Jun 20, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Viagenpumatucel-L: Phase Ib/II data

Top-line data from 3 patients with advanced NSCLC previously treated with >=1 prior therapy in the open-label, U.S. Phase Ib/II DURGA trial showed that once-weekly injections of 1x10 7 cells of HS-110 for 18 weeks plus Opdivo nivolumab led to 2 responses. Heat said both responders...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >